101 Morgan Lane
About WuXi AppTec
Established in December 2000, WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services throughout the drug R&D process. Our services are designed to help our worldwide customers shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions.
The company built its initial capabilities around discovery chemistry and has further enhanced the integrated services with analytical services, bio-analytical services, process research, process development services, API manufacturing services, DMPK/ADME, discovery biology, pharmacology, formulation, toxicology, genomic services, biologics manufacturing services, antibody and biological research reagent manufacturing and sales, and most recently clinical research and regulatory services.
WuXi AppTec has developed from four founders and a single laboratory in December 2000 to 14,000 employees and 6 million square feet of laboratory and manufacturing space, including facilities under construction. The company is actively improving its capabilities and capacity through new expansions in its global business. Capitalizing on the great advantage of conducting R&D services, WuXi AppTec is building an alternative R&D engine to serve the global life-science industry.
107 articles with WuXi AppTec
STA Pharmaceutical Co., Ltd., (WuXi STA), a subsidiary of WuXi AppTec, announces that its active pharmaceutical ingredient (API) R&D and manufacturing facility located in Changzhou, China has secured Pre-Approval Inspection (PAI) for two APIs from the U.S. Food and Drug Administration (FDA) – with no Form 483s issued.
STA Pharmaceutical Co., Ltd. announces that it has signed an investment agreement with the government of Shanghai Jinshan District to build a new R&D center.
It’s no secret that China has become an ever-increasing important component for drug development. Not only is the country seen as a lucrative market for drugs, entities within the country are making heavy investments in the global biotech industry.
WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, today announced the opening of its expanded Laboratory Testing Division (LTD) facility in New Jersey.
With the cutting of a ribbon more than 200 new jobs are expected to be created as China-based WuXi AppTec officially opened its expanded Laboratory Testing Division (LTD) facility in New Jersey.
WuXi AppTec announced the opening of its expanded Laboratory Testing Division (LTD) facility in New Jersey.
Phoenix Molecular Designs Announces Manufacturing Collaboration with WuXi STA to advance PMD-026 toward IND
PMD-026 is the first RSK inhibitor to demonstrate potential disease-modifying properties in triple-negative breast cancer
Nohla Therapeutics Selects Advanced Therapies Business Unit of WuXi AppTec to Manufacture Universal Donor Cell Therapies
“We are excited to partner with WuXi AppTec Advanced Therapies to gain their expertise and cGMP manufacturing capabilities to support the ongoing development and anticipated global commercial demand for our lead cell therapy program, NLA101,” said Katie Fanning, President and Chief Executive Officer of Nohla.
JW Therapeutics, a clinical stage biopharma company founded by Juno Therapeutics and WuXi AppTec Group, has closed a Series A financing worth $90 million.
The new online platform allows users to input search parameters by utilizing one of two molecular structure drawing tools provided on the site, or by uploading search data files.
WuXi AppTec and Mayo Clinic announced today a joint venture to co-develop and deliver clinical diagnostic services in China.
The incubator will be located at Merck Serono's current facilities in Yavne, a town in central Israel.
In collaboration with its partners, the Stem Cell Center aims to accelerate the preclinical/clinical development, and commercialization of stem cell, cellular and gene-modified therapies via end-to-end solutions and targeted services to advance assets from candidate identification through market authorization and improve the probability of clinical and commercial success.
WuXi AppTec, a China CRO/CMO, will acquire ResearchPoint Global, of Texas, a global clinical-stage contract research company, to extend the reach of its own clinical CRO coverage.
STA Pharmaceutical, a WuXi AppTec company, has announced plans to launch a new transition metal catalysis center at their integrated API process R&D and manufacturing site in Changzhou China.
WuXi AppTec will acquire a global clinical-stage contract research company, ResearchPoint Global, of Austin, Texas.
WuXi AppTec Immunotherapy Report: Biotech Sector Will Drive Biggest Advancements In Decades On Cancer Treatments